Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BMS 986371

Drug Profile

BMS 986371

Alternative Names: BMS-986371; CC-99677

Latest Information Update: 26 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celgene Corporation
  • Class Anti-inflammatories
  • Mechanism of Action MAP-kinase-activated kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Ankylosing spondylitis; Inflammation

Most Recent Events

  • 26 Oct 2023 Discontinued - Phase-I for Inflammation (In volunteers) in USA, United Kingdom (PO) prior to October 2023 (Bristol-Myers Squibb pipeline, October 2023)
  • 26 Oct 2023 Discontinued - Phase-II for Ankylosing spondylitis in Turkey, Spain, Poland, Romania, Poland, Czech Republic, China, USA, Germany (PO) prior to October 2023 (Bristol-Myers Squibb pipeline, October 2023)
  • 15 Feb 2023 Celgene terminates a phase-II clinical trials in Ankylosing spondylitis due to lack of efficacy in Germany, Turkey, Spain, Romania, Poland, Czech Republic, China, USA (PO) (NCT04947579)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top